

## BenevolentAI is a leading, clinical-stage AI drug discovery company

Through the combined capabilities of our AI discovery platform, scientific expertise and wet lab facilities, we are well positioned to deliver novel drug candidates with a higher probability of clinical success.

**300+**

World-class scientists & technologists

**50%**

Advanced degrees (PhD or MD)

**40%**


Data science, software engineering & automation

**35%**

Biology, chemistry & development

## The Benevolent Knowledge Graph: Our Biomedical Data Engine

Our Knowledge Graph uniquely combines proprietary, public and licensed data from scientific literature, patents, genetics, chemistry, clinical trials, electronic health records and more. We consciously integrate as many orthogonal data sources as possible in order to gain a detailed understanding of complex disease biology.



## The Benevolent Platform™

AI-augmented tools inform decision-making at every stage of drug discovery and accelerate the development of **de-risked novel drug candidates**.



### Knowledge

Our knowledge tools enable scientists to interrogate data and disease networks within the graph to answer complex biological questions



### Precision Medicine

Patient-centric target identification relies on human data to increase the chances of a drug being efficacious. We also develop biomarkers to identify patients most likely to respond to treatment to improve the likelihood of clinical trial success



### Target Identification

Machine learning models predict the most biologically relevant and progressible drug target hypotheses and rank them for triage by drug discovery scientists



### Molecular Design

Structure-based design, virtual screening and machine learning optimise for compound activity and selectivity to rapidly design highly quality drug candidates to take into clinical trials

## Benevolent<sup>AI</sup> Business Model


A highly versatile, diversified and de-risked business model.

### Wholly owned assets

We develop new drug programmes for core therapeutic areas in-house and selectively out-license or partner other assets

### Strategic collaborations

Collaborate with partners on new drug discovery and commercialisation to maximise the value of our platform and pipeline





## Partners



## Pipeline

Demonstrated impact and clinical validation of our AI platform and approach in drug discovery



**20+**  
Platform-generated disease programmes

In-house Atopic Dermatitis asset in <b>Phase 1 clinical trials</b>	Novel targeted in-house ulcerative colitis candidate in <b>IND-enabling studies</b>	<b>Novel CKD target</b> delivered to AstraZeneca's portfolio in ongoing successful collaboration	<b>EUA FDA Approval</b> for our AI-driven drug repurposing hypothesis of Eli Lilly drug for COVID-19
--	---	--	--

## Combined Company Board



## Contact

